Literature DB >> 23604119

Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.

K S Hill1, E Erdogan1, A Khoor2, M P Walsh1, M Leitges3, N R Murray1, A P Fields1.   

Abstract

Protein kinase C alpha (PKCα) can activate both pro- and anti-tumorigenic signaling depending upon cellular context. Here, we investigated the role of PKCα in lung tumorigenesis in vivo. Gene expression data sets revealed that primary human non-small lung cancers (NSCLC) express significantly decreased PKCα levels, indicating that loss of PKCα expression is a recurrent event in NSCLC. We evaluated the functional relevance of PKCα loss during lung tumorigenesis in three murine lung adenocarcinoma models (LSL-Kras, LA2-Kras and urethane exposure). Genetic deletion of PKCα resulted in a significant increase in lung tumor number, size, burden and grade, bypass of oncogene-induced senescence, progression from adenoma to carcinoma and a significant decrease in survival in vivo. The tumor promoting effect of PKCα loss was reflected in enhanced Kras-mediated expansion of bronchio-alveolar stem cells (BASCs), putative tumor-initiating cells, both in vitro and in vivo. LSL-Kras/Prkca(-/-) mice exhibited a decrease in phospho-p38 MAPK in BASCs in vitro and in tumors in vivo, and treatment of LSL-Kras BASCs with a p38 inhibitor resulted in increased colony size indistinguishable from that observed in LSL-Kras/Prkca(-/-) BASCs. In addition, LSL-Kras/Prkca(-/-) BASCs exhibited a modest but reproducible increase in TGFβ1 mRNA, and addition of exogenous TGFβ1 to LSL-Kras BASCs results in enhanced growth similar to untreated BASCs from LSL-Kras/Prkca(-/-) mice. Conversely, a TGFβR1 inhibitor reversed the effects of PKCα loss in LSL-Kras/Prkca(-/-) BASCs. Finally, we identified the inhibitors of DNA binding (Id) Id1-3 and the Wilm's Tumor 1 as potential downstream targets of PKCα-dependent tumor suppressor activity in vitro and in vivo. We conclude that PKCα suppresses tumor initiation and progression, at least in part, through a PKCα-p38MAPK-TGFβ signaling axis that regulates tumor cell proliferation and Kras-induced senescence. Our results provide the first direct evidence that PKCα exhibits tumor suppressor activity in the lung in vivo.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23604119      PMCID: PMC3895109          DOI: 10.1038/onc.2013.147

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  61 in total

1.  Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.

Authors:  Astrid M Eder; Xiaomei Sui; Daniel G Rosen; Laura K Nolden; Kwai Wa Cheng; John P Lahad; Madhuri Kango-Singh; Karen H Lu; Carla L Warneke; Edward N Atkinson; Isabelle Bedrosian; Khandan Keyomarsi; Wen-lin Kuo; Joe W Gray; Jerry C P Yin; Jinsong Liu; Georg Halder; Gordon B Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-22       Impact factor: 11.205

2.  Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity.

Authors:  Roderick P Regala; Capella Weems; Lee Jamieson; John A Copland; E Aubrey Thompson; Alan P Fields
Journal:  J Biol Chem       Date:  2005-07-01       Impact factor: 5.157

3.  Identification of bronchioalveolar stem cells in normal lung and lung cancer.

Authors:  Carla F Bender Kim; Erica L Jackson; Amber E Woolfenden; Sharon Lawrence; Imran Babar; Sinae Vogel; Denise Crowley; Roderick T Bronson; Tyler Jacks
Journal:  Cell       Date:  2005-06-17       Impact factor: 41.582

4.  Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer.

Authors:  Roderick P Regala; Capella Weems; Lee Jamieson; Andras Khoor; Eric S Edell; Christine M Lohse; Alan P Fields
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

5.  Protein kinase Ciota activity is necessary for Bcr-Abl-mediated resistance to drug-induced apoptosis.

Authors:  L Jamieson; L Carpenter; T J Biden; A P Fields
Journal:  J Biol Chem       Date:  1999-02-12       Impact factor: 5.157

6.  Phorbol ester-induced G1 phase arrest selectively mediated by protein kinase Cdelta-dependent induction of p21.

Authors:  Motonori Nakagawa; Jose Luis Oliva; Devashish Kothapalli; Alaina Fournier; Richard K Assoian; Marcelo G Kazanietz
Journal:  J Biol Chem       Date:  2005-07-28       Impact factor: 5.157

7.  A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells.

Authors:  Melody Stallings-Mann; Lee Jamieson; Roderick P Regala; Capella Weems; Nicole R Murray; Alan P Fields
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

8.  Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.

Authors:  Stuart A Grossman; Jane B Alavi; Jeffrey G Supko; Kathryn A Carson; Regina Priet; F Andrew Dorr; John S Grundy; Jon T Holmlund
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

9.  PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis.

Authors:  Trever G Bivona; Steven E Quatela; Brian O Bodemann; Ian M Ahearn; Michael J Soskis; Adam Mor; John Miura; Heidi H Wiener; Latasha Wright; Shahryar G Saba; Duke Yim; Adam Fein; Ignacio Pérez de Castro; Chi Li; Craig B Thompson; Adrienne D Cox; Mark R Philips
Journal:  Mol Cell       Date:  2006-02-17       Impact factor: 17.970

10.  Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.

Authors:  Luis Paz-Ares; Jean-Yves Douillard; Piotr Koralewski; Christian Manegold; Egbert F Smit; José Miguel Reyes; Gee-Chen Chang; William J John; Patrick M Peterson; Coleman K Obasaju; Michael Lahn; David R Gandara
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

View more
  20 in total

1.  Protein kinase Cα mediates erlotinib resistance in lung cancer cells.

Authors:  Mahlet B Abera; Marcelo G Kazanietz
Journal:  Mol Pharmacol       Date:  2015-02-27       Impact factor: 4.436

Review 2.  Protein kinase C as a tumor suppressor.

Authors:  Alexandra C Newton
Journal:  Semin Cancer Biol       Date:  2017-05-02       Impact factor: 15.707

Review 3.  Protein kinase C and cancer: what we know and what we do not.

Authors:  R Garg; L G Benedetti; M B Abera; H Wang; M Abba; M G Kazanietz
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

Review 4.  Protein kinase C in cancer: The top five unanswered questions.

Authors:  Mariana Cooke; Andrew Magimaidas; Victoria Casado-Medrano; Marcelo G Kazanietz
Journal:  Mol Carcinog       Date:  2017-03-10       Impact factor: 4.784

Review 5.  PHLPPing the balance: restoration of protein kinase C in cancer.

Authors:  Hannah Tovell; Alexandra C Newton
Journal:  Biochem J       Date:  2021-01-29       Impact factor: 3.857

6.  Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor.

Authors:  Corina E Antal; Andrew M Hudson; Emily Kang; Ciro Zanca; Christopher Wirth; Natalie L Stephenson; Eleanor W Trotter; Lisa L Gallegos; Crispin J Miller; Frank B Furnari; Tony Hunter; John Brognard; Alexandra C Newton
Journal:  Cell       Date:  2015-01-22       Impact factor: 41.582

7.  PKCε Is Required for KRAS-Driven Lung Tumorigenesis.

Authors:  Rachana Garg; Mariana Cooke; Fernando Benavides; Martín C Abba; Michelle Cicchini; David M Feldser; Marcelo G Kazanietz
Journal:  Cancer Res       Date:  2020-09-29       Impact factor: 12.701

Review 8.  The complexities of PKCα signaling in cancer.

Authors:  Adrian R Black; Jennifer D Black
Journal:  Adv Biol Regul       Date:  2020-11-23

9.  MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.

Authors:  Hui Chen Pai; Sunil Kumar; Chien-Chang Shen; Jing Ping Liou; Shiow Lin Pan; Che Ming Teng
Journal:  PLoS One       Date:  2015-04-14       Impact factor: 3.240

10.  The deubiquitinase USP16 functions as an oncogenic factor in K-RAS-driven lung tumorigenesis.

Authors:  Guiqin Xu; Zhaojuan Yang; Yizong Ding; Yun Liu; Li Zhang; Boshi Wang; Ming Tang; Tiantian Jing; Kun Jiao; Xiaoli Xu; Zehong Chen; Lvzhu Xiang; Chen Xu; Yujie Fu; Xiaojing Zhao; Weilin Jin; Yongzhong Liu
Journal:  Oncogene       Date:  2021-07-22       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.